InVivo Therapeutics Holdings Overview

InVivo Therapeutics Holdings Selling, General & Admin

Selling, General & Admin expenses for NVIV.

Quarterly SG&A Expenses

$2.13M

↑ 30.21% YoY

As of Sep 30, 2023

Annual SG&A Expenses (TTM)

$5.78M

↓ 0.99% YoY

Trailing 12 months ending Sep 30, 2023

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin